Tesaro (Tesaro) Accounts Receivable : $31.4 Mil (As of Sep. 2018)

View and export this data going back to 2012. Start your Free Trial

What is Tesaro Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Tesaro's accounts receivables for the quarter that ended in Sep. 2018 was $31.4 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Tesaro's Days Sales Outstanding for the quarter that ended in Sep. 2018 was 44.44.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Tesaro's Net-Net Working Capital per share for the quarter that ended in Sep. 2018 was $-5.21.

Tesaro Accounts Receivable Historical Data

The historical data trend for Tesaro's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tesaro Accounts Receivable Chart

Tesaro Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Accounts Receivable

Get a 7-Day Free Trial

0.68

5.34

53.42

Tesaro Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Accounts Receivable	Get a 7-Day Free Trial															27.68	53.42	44.18	35.68	31.36

Tesaro Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.

Tesaro Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Tesaro's Days Sales Outstanding for the quarter that ended in Sep. 2018 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	31.362	/	64.399	*	91
=	44.44

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Tesaro's accounts receivable are only considered to be worth 75% of book value:

Tesaro's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2018 is calculated as:

	Net-Net Working Capital Per Share
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(476.812	+	0.75 * 31.362	+	0.5 * 108.822	-	841.632
-	0	-	0)	/	55.035
=	-5.21

Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.

Tesaro Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Tesaro's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.

Tesaro (Tesaro) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tesaro Inc (NAS:TSRO) » Definitions » Accounts Receivable

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.tesarobio.com

Tesaro is an oncology-focused biopharmaceutical company with a focus on developing treatments for cancer. Upon successful development and regulatory approval of any of its product candidates, the company intends to pursue commercialization in key product markets, including North America, Europe, and China. Tesaro is currently focused on commercializing products directly in North America, and directly or in partnership with established companies in Europe and China. The company's strategy is to identify, acquire, and develop promising drug candidates, and to commercialize cancer therapeutics that are potentially safer and more effective than existing treatments.

Executives

Mary Lynne Hedley	director, officer: President & COO	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Kavita Patel	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Huber Martin H. Jr.	officer: SVP & Chief Medical Officer	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Moulder Leon O Jr	director, officer: Chief Executive Officer	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
James O Armitage	director	C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
Timothy R Pearson	officer: Exec. VP, CFO	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Garry A Nicholson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Grant C. Bogle	officer: Sr. VP, Chief Commercial Ofc	C/O TESARO, INC. 1000 WINTER STREET, SUITE 3300 WALTHAM MA 02451
Nea Partners 13, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Collier Earl M Jr	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Beth C Seidenberg	director
Joseph L Farmer	officer: Sr VP, Gen Counsel & Secretary	C/O TESARO, INC. 1000 WINTER STREET, SUITE 3300 WALTHAM MA 02451
Patrick J Kerins	10 percent owner